Comparative Pharmacology
Head-to-head clinical analysis: TIVICAY versus VIRAC REX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TIVICAY versus VIRAC REX.
TIVICAY vs VIRAC REX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration, which is essential for HIV replication.
VirAcRex is a direct-acting antiviral that inhibits the viral RNA-dependent RNA polymerase (NS5B) by acting as a chain terminator, thereby blocking viral replication.
50 mg orally once daily, or 50 mg twice daily when coadministered with potent UGT1A1 inducers (e.g., rifampin). For INSTI-naive patients: 50 mg once daily. For INSTI-experienced patients with suspected resistance: 50 mg twice daily.
300 mg orally once daily with or without food.
None Documented
None Documented
Terminal elimination half-life approximately 14 hours (range 11-20 hours) in healthy subjects; supports once-daily dosing with a low pharmacokinetic boost.
Terminal elimination half-life: 2.5-3.5 hours; clinical context: requires thrice-daily dosing to maintain therapeutic levels.
Primarily metabolized by UGT1A1 with minor CYP3A4 contribution; 53% of dose excreted in feces (31% as unchanged drug) and 33% in urine (1% unchanged).
Renal: 30-40% unchanged; biliary/fecal: 50-60% as metabolites; <10% in feces as parent drug.
Category C
Category C
Antiretroviral, integrase inhibitor
Antiretroviral